Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Daniela A BotaThomas H TaylorDavid E PiccioniChristopher M DumaRenato V LaRoccaSantosh KesariJose A CarrilloMehrdad AbediRobert D AikenFrank P K HsuXiao-Tang KongCandace HsiehPeter G BotaGabriel I NistorHans S KeirsteadRobert O Dillman

Published in: Journal of experimental & clinical cancer research : CR (2022)

NCT, NCT03400917 , Registered 10 January 2018.

Keyphrases

newly diagnosed
dendritic cells
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
cell therapy
immune response
patient reported outcomes
drug delivery
double blind